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INTRODUCTION 
 
Epistaxis is the most common acute presentation to ENT services in the UK.  In 
the financial year 2009-10, 23,723 epistaxis-related admissions were recorded 
in the National Health Service Hospital Episode Statistics for England and 
Wales1.  Despite this high incidence, there are currently no nationally accepted 
guidelines for its management2. A recent multi-centred pilot audit3 undertaken 
by INTEGRATE (The National ENT Trainee Research Network) demonstrated a 
wide variation in practice.  The goal of this multidisciplinary consensus 
guideline was to develop agreed evidenced-based recommendations for the 
management of this common condition.  This guideline was then utilized as the 
gold-standard for the subsequent national audit of epistaxis management4. 
 
METHODS 
Recommendations were developed using an AGREE II framework5, a method 
successfully utilized in the 2009 Hereditary Haemorrhagic Telangiectasia 
guidelines6.  Consensus member disagreement was managed using an 
adaptation of the method utilized within RAND/UCLA appropriateness 
studies7.  The use of established guideline generation methodology sought to 
provide rigour in development, despite an expected paucity in high-level 
evidence. 
 
Scope and Purpose 
Representatives from the ENT-UK Clinical Audit and Practice Advisory Group 
(CAPAG) and the British Rhinological Society (BRS) approached INTEGRATE 
highlighting the requirement for nationally accepted standards of care in 
epistaxis. This guideline seeks to recommend evidence-based best practice for 
the hospital management of epistaxis of all severity in adults, within the 
context of commonly associated comorbidities known to affect outcome.  We 
exclude guidance on paediatric epistaxis, hereditary haemorrhagic 
telangiectasia and other specific haematological conditions. 
 
Stakeholder Involvement 
The organising committee was composed of 7 junior clinicians including a 
nominated chair and 2 executive senior members.  The organising committee 
were responsible for developing the consensus methodology and co-ordinating 
a multi-faceted systematic review of the relevant literature.  The consensus 
panel was composed of patients, ENT surgeons and representative experts 
from allied specialties involved in the management of epistaxis from across the 
UK. An open invite was extended to all consultant members of BRS and ENTUK 
to participate in the consensus panel as ENT representatives.  Allied specialty 
consultants and patient representatives were invited individually following 
identification by the steering committee as appropriate experts in their fields. 
Individuals from health economics, emergency medicine, haematology, 
interventional radiology, general ENT and rhinology all contributed to the 
guidelines. 
 
Rigour of Development  
For the purposes of this consensus, the management of epistaxis was divided 
into 5 domains (initial assessment, cautery, intranasal agents, haematological 
factors, surgery and radiological intervention).  Each domain was assigned co-
authors from locations throughout the UK. Within the domains, a total of 15 
systematic reviews8-12 were conducted, with the support of Cambridge and 
Exeter Universities plus the Defence Military Library. A robust yet pragmatic 
methodology was followed including validated assessment of bias13-14, 
capturing all relevant published evidence of level 3 and above.  
The data synthesis and full-text included articles were made available to the 
consensus panel members, prior to domain co-authors presenting their 
findings at a guidelines conference held in Leeds on the 19th May 2016.  A 
consensus panel discussion was held following each domain presentation, 
facilitated by the chair of the consensus panel, seeking to generate 
management recommendations.  These discussions were digitally recorded 
and converted to a written consensus matrix by the steering committee.  Each 
recommendation was then linked with the level of evidence15 supporting each 
statement and a GRADE score16 explaining the strength of recommendation in 
context of the evidence plus the perceived harm and benefit.  The draft matrix 
was then returned to the consensus panel electronically for 2 separate rounds 
of comments and subsequent adjustment. 
 
Following final consensus matrix adjustment, the level of consensus agreement 
was then sought by requesting consensus panel members to independently 
assign an agreement rating from 0-10 for each recommendation.  0 
represented complete disagreement with the statement and 10 absolute 
agreement.  Panel members were asked to abstain from comment when the 
specific recommendation was felt to be outside their clinical remit.  
Statements achieving a median rating of <7 were excluded from the consensus 
matrix.  Disagreement was defined as statements achieving a median rating ≥7 
but with individual ratings of <4.  In these cases, outlying panel members were 
given the opportunity to revise their score if desired.  All retained statements 
were reported with their median consensus agreement rating, range of ratings 
and an asterisk annotated where ratings were revised following disagreement.  
 It is anticipated that the consensus recommendations will be updated 
following completion of each cycle of the national audit of epistaxis 
management4. 
 
RECOMMENDATIONS 
Initial Assessment (fig. 1) 
Despite low and very low quality of evidence, a number of strong 
recommendations were made.  This was achieved due the lack of perceived 
risk of recommendation versus consensus agreed benefit.  Recommendations 
centred round the use of a structured ABC approach and the recording of key 
comorbidities with evidence available to support their impact on patient 
outcome.  Very low quality or absence of evidence limited the strength of 
recommendation regarding the use of well-established first aid methods as 
well as specific statements regarding the clinical examination methods and 
investigation of patients presenting with epistaxis.  Despite these limitations 
there were consistently high agreement rating levels with minimal 
disagreement in accepted statements. 
 
Cautery (fig. 2) 
Low and very low quality evidence again limited the strength of 
recommendations made regarding intranasal cautery (fig. 3).  Strong 
recommendations were made supporting cautery as a first line treatment in all 
patients, but that cautery should be targeted at identified points of bleeding.  
Weak recommendations were made regarding the need for specific cautery 
training, the use of topical vasoconstrictors, electrocautery in preference to 
silver nitrate and advanced clinical examinations when a bleeding point is not 
initially identified with anterior rhinoscopy.  There were high median 
agreement ratings for all statements with no disagreement. 
 
Intranasal Agents (fig.3) 
This domain was unusually supported, in places, by moderate and strong 
quality evidence.  This allowed the strong recommendation of non-dissolvable 
anterior nasal packs as an effective haemostatic intervention in stipulated 
clinical scenarios when placed by individuals specifically trained in their use.  
Consensus opinion strongly supported the use of targeted cautery following 
removal of non-dissolvable packs despite no supporting evidence.  This was 
based on a perceived significant benefit balanced against any potential harm 
or cost.  The consensus panel weakly recommended the use of Rapid Rhino 
packs over Merocel as the non-dissolvable pack of choice, as well as 
recommendation regarding the length of time a pack should remain in-situ and 
how long patients should be observed following pack removal.  Despite median 
agreement ratings largely between 8 and 9.5 there were several instances of 
disagreement. 
 
Recommendations regarding the use of dissolvable packs and haemostatic 
agents were limited by a paucity of quality evidence, the diversity of available 
products and a lack of clarity regarding where in the treatment of epistaxis 
these products should be employed.  3 of the 4 recommendations received low 
agreement ratings of 7 or 7.5 and there was 1 instance of disagreement.  
 
Anti-thrombotic therapy (fig. 4) and haematological factors (fig. 5)  
Despite no epistaxis-specific supporting evidence, several weak 
recommendations were made regarding the management of warfarin, direct 
oral anticoagulants (DOAC) and heparin.  These centred around the 
extrapolation of generic national guidelines and maintaining a low threshold 
for seeking case-specific haematological advice.  Despite weak strength of 
recommendations there was universally high levels of median agreement 
rating with no instances of disagreement. 
 
Similarly, there was no evidence to recommend an epistaxis-specific treatment 
strategy for the management of ongoing antiplatelet therapy.  Consensus 
opinion recommended the continuation of such agents in uncomplicated cases 
and the involvement of allied specialties in complex or refractory cases.  Levels 
of agreement were high without disagreement. 
 
Transfusion strategies for epistaxis were again based on evidence unrelated to 
the condition.  Despite this, a number of strong recommendations were made 
for the use of elements of The British Committee for Standards in Haematology 
guidelines for the management of major haemorrhage17.  Median agreement 
ratings were 10 for recommendations, with 1 instance of disagreement. 
 
Tranexamic acid (TXA) use in epistaxis benefited from moderate quality 
evidence, however, with inconsistent findings.  As a result, weak 
recommendations for its use were made with median rater agreement of 7 
and 8 with disagreement in both epistaxis specific statements.  National 
guidelines regarding the use of TXA in defined major haemorrhage were 
strongly recommended and received a median agreement rating of 10 without 
disagreement. 
 
Surgery and Radiological Intervention (fig. 6) 
Weak strength recommendations were made regarding the role of surgical and 
radiological intervention in epistaxis.  This was limited by the lack of quality 
evidence in this area.  Despite this, consensus agreement was high for the 
identified clinical scenarios requiring treatment escalation and that surgery 
should be preferred to radiological intervention.  However, interventional 
radiologists were outnumbered by ENT surgeons on the consensus panel which 
may have biased the median agreement rating. 
 
CONCLUSIONS 
These consensus recommendations are based on a wide-ranging review of the 
relevant literature and established and rigorous methods of guideline 
generation. As a result, it is envisaged that the findings of this document 
should be of use to all hospital clinicians managing acute epistaxis.  Readers 
should remain cognisant that the evidence identified to support this guideline 
is largely of low or very low quality and expert consensus opinion was often 
required to reach recommendations. Whilst this should not undermine the 
utility of the document, caution should be use when implementing these 
findings.  These recommendations will continue to be updated as new 
evidence comes to light. 
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